Home >  Registry
     
 
 Protocol Registry Trial Results IFPMA Background Links
About this Registry

This registry serves as a global repository for information on ongoing Roche Pharmaceuticals Phase II to Phase IV clinical studies, Phase I studies in patients and Roche Diagnostics interventional studies on advanced diagnostic products.

For More Information 

Common Questions
More Frequently Asked Questions 
Overview of Clinical Trials 
Glossary of Terms 
Phase Definitions 
Field Definitions 
Roche Clinical Trial Global Policy 
Site Provided by Thomson CenterWatch

Breast Cancer

  • A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
    Not yet recruiting


  • BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
    Recruiting


  • A Study to Assess Xeloda (Capecitabine) in Patients With Locally Advanced or Metastatic Breast Cancer
    Recruiting


  • A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
    Recruiting


  • A Continuation Study of Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer
    Recruiting


  • A Study of Pertuzumab in Combination With Herceptin in Patients With Metastatic Breast Cancer.
    Recruiting


  • A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
    Recruiting


  • A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
    Recruiting


  • A Study of Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.
    Recruiting


  • THOR study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.
    Recruiting


  • BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
    Recruiting


  • A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
    Recruiting


  • A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer.
    Recruiting


  • A Study of Avastin (Bevacizumab) and Sequential Chemotherapy in Patients With Primary HER2 Negative Operable Breast Cancer.
    Recruiting


  • A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Docetaxel in Patients With Inflammatory or Locally Advanced Breast Cancer.
    Recruiting


  • A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
    Recruiting


  • A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Metastatic or Locally Advanced Breast Cancer
    No longer recruiting


  • A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
    No longer recruiting


  • A Study to Evaluate the Efficacy and Safety of Herceptin (Trastuzumab) in Combination With an Aromatase Inhibitor in Patients With Metastatic Breast Cancer
    No longer recruiting


  • A Study of Herceptin (Trastuzumab) in Women With c-erbB2-Positive Metastatic Breast Cancer
    No longer recruiting


  • HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
    No longer recruiting


  • A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer
    No longer recruiting


  • A Study of Xeloda (Capecitabine) in Women With High-Risk Breast Cancer
    No longer recruiting


  • A Study of Xeloda (Capecitabine) in Patients With Metastatic or Locally Advanced Breast Cancer
    No longer recruiting


  • A Study of Xeloda (Capecitabine) Prior to Surgery in Women With Breast Cancer
    No longer recruiting


  • XeNA study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer
    No longer recruiting


  • A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
    No longer recruiting


  • A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
    No longer recruiting


  • A Study of Xeloda (Capecitabine) in Patients With Advanced Breast Cancer
    Completed


  • A Study of Pertuzumab in Patients With Metastatic Breast Cancer
    Completed


  • A Study of Epothilone D in Patients With Metastatic Breast Cancer
    Completed


  • A Study of Herceptin (Trastuzumab) in Combination Therapy in Patients With Metastatic Breast Cancer
    Completed


  • A Study of Herceptin (Trastuzumab) Monotherapy in Women With Metastatic Breast Cancer
    Completed


  • A Study of Herceptin (Trastuzumab) in Women With HER2-Positive Advanced and/or Metastatic Breast Cancer
    Completed


  • An Expanded Access Program of Neulastim (Pegfilgrastim) in Patients With Breast Cancer
    Completed


  • A Study of Epothilone D in Combination With Herceptin (Trastuzumab) in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer.
    Completed


  • A PK-Loading Study of q3w Herceptin (Trastuzumab) Monotherapy in Women With HER2 Positive Metastatic Breast Cancer.
    Completed


  • A Dose-Finding Study of Tarceva (Erlotinib) Given After Vinorelbine and Xeloda in Patients With Metastatic Breast Cancer.
    Completed


  • A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Metastatic Breast Cancer
    Completed


  • A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Primary Breast Cancer
    Completed


    		•

    © 1996-2008 F.Hoffmann-La Roche Ltd See our legal Statement